research Bitemporal alopecia areata
The paper concludes that recognizing bitemporal alopecia areata is important for early treatment and preventing its progression.
Search
for
Sort by
Research
690-720 / 1000+ results 
research Alopecia universalis treated with simvastatin/ezetimibe, minoxidil, and prednisolone in a 6‐year‐old girl
A 6-year-old girl with alopecia universalis regrew most of her hair after treatment with simvastatin/ezetimibe, minoxidil, and prednisolone.
research Female pattern hair loss, biological ageing and the Leiden Longevity study
Women with aging signs and heart issues have higher hair loss risk, which may predict shorter lifespan and affect attractiveness.
research Limited Effectiveness of Platelet-Rich-Plasma Treatment on Chronic Severe Alopecia Areata
Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.
research Epigenetic modifications may explain the relative protection of occipital hair follicles from androgenetic alopecia in men
Epigenetic changes might protect occipital hair from male pattern baldness.
research Oral cyclosporin does not arrest progression of androgenetic alopecia.
Oral cyclosporin doesn't stop hair loss.
research Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
The study investigates NF-κB signalling in CYLD cutaneous syndrome (CCS) tumours to identify potential drug targets. Researchers used transcriptomics, proteomics, and single-cell RNA sequencing on patient-derived CCS tumour cells, revealing evidence of non-canonical NF-κB signalling with increased p100 to p52 processing and RelB protein expression. IκB kinase alpha (IKKα) was identified as a candidate target, and a novel IKKα inhibitor (SU1644) was tested on CCS tumour spheroid cultures, showing reduced tumour viability. The findings support the potential use of topical IKKα inhibitors as a preventive treatment for CCS.
research Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study
Alopecia areata affects 1.2% to 2.3% of Australians, with many unaware of treatment options.
research Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial
Sublingual minoxidil safely increases hair growth in transgender people on testosterone therapy.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
research Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
research The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy
Facial hair loss and psychosocial issues are crucial in deciding treatment for alopecia areata.
research Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research A multicentre cohort study of the clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distribution
Fibrosing alopecia can be stabilized or improved with anti-inflammatory treatments and hair growth agents.
research 61720 The effect of sublingual minoxidil on androgenetic alopecia in transgender individuals receiving testosterone for gender-affirmation: A 24-week single-centre double-blinded, randomized, placebo-controlled clinical trial
Sublingual minoxidil significantly improves hair growth in transgender individuals on testosterone therapy.
research Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
research You cannot go bald without first, losing your hair: Telogen effluvium is a precursor to, prerequisite for and potentially an incitant to common baldness in men
Hair loss (telogen effluvium) happens before male pattern baldness.
research Scalp hair repigmentation after radiotherapy
A 76-year-old man's grey hair turned back to its original color after radiotherapy.
research Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
research COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
research Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
The study within the ALLEGRO clinical trial program assessed 832 patients with alopecia areata (AA) to identify predictors of long-term scalp hair regrowth following ritlecitinib treatment. Key predictors for achieving a SALT score ≤20 at 24 months included baseline SALT score, SALT score at Month 6, non-AT/AU type, duration of AA since diagnosis, and duration of significant scalp hair loss at baseline. These findings indicate that certain patient characteristics can predict treatment outcomes, which may help optimize treatment decisions for AA. However, the predictive models are not yet validated for clinical practice and should not replace professional medical judgment.
research Pericardial Disorders Occurring during Open Label Study of 3747 Patients Treated with Systemic Minoxidil
Low-dose oral minoxidil is safe for the heart.
research Combination of oral minoxidil and bicalutamide for the treatment of female pattern hair loss in adolescents
Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Sublingual Minoxidil Increases Fibre Diameter in Male Androgenetic Alopecia. - A proxy for Reversal of Hair Follicle Miniaturization.
Sublingual minoxidil increases hair thickness in men with hair loss.
research Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double‐blind randomized clinical trial
Sublingual and oral minoxidil are equally effective for hair growth, but sublingual causes fewer palpitations.